Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Core Viewpoint - Moleculin Biotech, Inc. has announced agreements for the immediate exercise of existing warrants, which will generate approximately $6.0 million in gross proceeds for the company [1][3]. Group 1: Financial Transactions - The company has entered into agreements for the immediate exercise of warrants to purchase up to 16,216,216 shares of common stock at an exercise price of $0.37 per share [1]. - Roth Capital Partners is acting as the financial advisor for this transaction [2]. - In exchange for the immediate exercise of the warrants, the company will issue new unregistered warrants for up to 64,864,864 shares at an exercise price of $0.55 per share, subject to shareholder approval [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [6]. - The lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [6][7]. - The company has initiated the MIRACLE trial, evaluating Annamycin in combination with cytarabine for AML treatment [7]. - Additionally, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122 for potential treatment of pathogenic viruses [8].